Navigation Links
Metabolic syndrome increases risk of both major types of primary liver cancer
Date:7/21/2011

Incidence rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have increased in the U.S. This population-based study publishing in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, found that metabolic syndrome significantly increases risk of developing these primary liver cancers.

According to data from the National Cancer Institute, 24,120 new cases of liver and intrahepatic bile duct cancer and close to 19,000 deaths from the diseases occurred in the U.S. in 2010. Major risk factors for HCC, the most common type of liver cancer, are chronic infection with hepatitis B and C viruses and excessive alcohol consumption. ICC, the second most common type of liver cancer, is associated with primary sclerosing cholangitis and inflammatory bowel disease. However, the cause of up to half of HCC and ICC remains unknown.

"There has been an increase in the incidence rates of liver cancerHCC and ICCin the U.S.," explains lead author Tania Welzel, M.D., with the National Cancer Institute and Klinikum der J.W. Goethe-Universitt. "While metabolic syndrome is a recognized risk factor for HCC and may also modify ICC risk, the magnitude of this effect has not been investigated on a large scale in the U.S." Metabolic syndrome comprises a group of medical conditions which include central obesity (excess abdominal-area weight), raised fasting glucose levels and diabetes mellitus, raised triglycerides, reduced HDL cholesterol, and hypertension.

For the present study, Dr. Welzel and colleagues examined the association between metabolic syndrome and development of primary liver cancers in the general U.S. population. Using the SEER-Medicare database, researchers identified individuals diagnosed with HCC or ICC between 1993 and 2005. A 5% sample of individuals residing in geographic regions similar to SEER registries was selected for comparison purposes. A total of 3649 HCC cases, 743 ICC cases, and 195953 individuals without cancer were identified and met study inclusion criteria.

The findings revealed that metabolic syndrome was present in 37% of persons who subsequently developed HCC and 30% of persons who developed ICC, compared to 17% of persons who didn't develop either cancer. Analyses showed metabolic syndrome was significantly associated with increased risk of HCC (odds ratio=2.13) and ICC (odds ratio=1.56). Individual components of metabolic syndromeimpaired fasting glucose level, dyslipoproteinemia, obesity and hypertensionwere more common among persons who developed either HCC or ICC patients than among persons who did not.

"Our findings show a 2-fold increased risk for HCC and a 1.56-fold increased risk for ICC in those individuals with pre-existing metabolic syndrome," concluded Dr. Welzel. "The risk of developing these primary liver cancers is significant for individuals with this condition. Due to the high prevalence of metabolic syndrome, even small increases in the absolute risk for HCC and ICC may contribute to the increasing liver cancer burden." The authors suggest that metabolic syndrome may be the source behind a number of the idiopathic HCC or ICC cases in the U.S. and efforts to control the worldwide epidemics of obesity and diabetes could reduce the liver cancer burden.


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related biology news :

1. Key metabolic pathway implicated in intractable form of breast cancer
2. Hold your breath: Air pollution plays role in cardiac, metabolic diseases
3. Study shows pine bark naturally improves kidney function in patients with metabolic syndrome
4. Metabolic cost of human sleep deprivation quantified by University of Colorado team
5. Birch bark ingredient comes with many metabolic benefits
6. Seaweed as biofuel? Metabolic engineering makes it a viable option
7. Longevity breakthrough: The metabolic state of mitochondria controls life span
8. Study finds low vitamin-d levels in northern California residents with metabolic syndrome
9. AgriLife scientist: Functional amino acids regulate key metabolic pathways
10. Imaging reveals key metabolic factors of cannibalistic bacteria
11. Native-like spider silk produced in metabolically engineered bacterium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/28/2016)... , April 28, 2016 Infosys ... (NYSE: INFY ), and Samsung SDS, a global ... that will provide end customers with a more secure, fast ...      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... but it also plays a fundamental part in enabling and ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... CO (PRWEB) , ... May 05, 2016 , ... ... diagnostics, is proud to support the National Stroke Association during National Stroke Awareness ... the association’s Facebook and Twitter pages throughout the month. CereScan will donate ...
(Date:5/4/2016)... ... May 04, 2016 , ... Looking for a gift ... premiere hands-on cooking experience. Offering everything from gourmet cooking classes to weekend culinary ... forget. , Guests that visit LaJollaCooks4u share an experience unlike any other. Each ...
(Date:5/4/2016)... ... , ... Proove Biosciences, Inc. , the commercial and research leader in ... . The partnership is designed to advance research in pain genetics in an effort ... With the new agreement, researchers at Proove Biosciences are able to collaborate with Luda ...
(Date:5/4/2016)...  Bayer today announced that a Phase III ... (regorafenib) tablets for the treatment of patients with ... endpoint of a statistically significant improvement in overall ... and safety of regorafenib in patients with HCC ... The safety and tolerability were generally consistent with ...
Breaking Biology Technology: